Logo image of CDTX

CIDARA THERAPEUTICS INC (CDTX) Stock Price, Quote, News and Overview

NASDAQ:CDTX - Nasdaq - US1717572069 - Common Stock - Currency: USD

63.31  +1.52 (+2.46%)

After market: 63.31 0 (0%)

CDTX Quote, Performance and Key Statistics

CIDARA THERAPEUTICS INC

NASDAQ:CDTX (7/31/2025, 8:10:05 PM)

After market: 63.31 0 (0%)

63.31

+1.52 (+2.46%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High66.94
52 Week Low10.14
Market Cap1.28B
Shares20.16M
Float19.94M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-11 2025-08-11
IPO04-15 2015-04-15


CDTX short term performance overview.The bars show the price performance of CDTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 50 100 150 200

CDTX long term performance overview.The bars show the price performance of CDTX in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300 400

The current stock price of CDTX is 63.31 USD. In the past month the price increased by 32.25%. In the past year, price increased by 432.91%.

CIDARA THERAPEUTICS INC / CDTX Daily stock chart

CDTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.85 333.88B
AMGN AMGEN INC 14.21 158.68B
GILD GILEAD SCIENCES INC 14.51 139.68B
VRTX VERTEX PHARMACEUTICALS INC N/A 117.32B
REGN REGENERON PHARMACEUTICALS 12.31 58.89B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 51.14B
ARGX ARGENX SE - ADR 72.31 41.02B
ONC BEONE MEDICINES LTD-ADR 7.72 32.59B
BNTX BIONTECH SE-ADR N/A 25.84B
INSM INSMED INC N/A 20.35B
SMMT SUMMIT THERAPEUTICS INC N/A 19.58B
BIIB BIOGEN INC 8 18.76B

About CDTX

Company Profile

CDTX logo image Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. The company is headquartered in San Diego, California. The company went IPO on 2015-04-15. The firm is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The firm is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.

Company Info

CIDARA THERAPEUTICS INC

6310 Nancy Ridge Dr Ste 101

San Diego CALIFORNIA 92121 US

CEO: Jeffrey Stein

Employees: 38

CDTX Company Website

CDTX Investor Relations

Phone: 18587526170

CIDARA THERAPEUTICS INC / CDTX FAQ

What is the stock price of CIDARA THERAPEUTICS INC today?

The current stock price of CDTX is 63.31 USD. The price increased by 2.46% in the last trading session.


What is the ticker symbol for CIDARA THERAPEUTICS INC stock?

The exchange symbol of CIDARA THERAPEUTICS INC is CDTX and it is listed on the Nasdaq exchange.


On which exchange is CDTX stock listed?

CDTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CIDARA THERAPEUTICS INC stock?

13 analysts have analysed CDTX and the average price target is 60.35 USD. This implies a price decrease of -4.68% is expected in the next year compared to the current price of 63.31. Check the CIDARA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CIDARA THERAPEUTICS INC worth?

CIDARA THERAPEUTICS INC (CDTX) has a market capitalization of 1.28B USD. This makes CDTX a Small Cap stock.


How many employees does CIDARA THERAPEUTICS INC have?

CIDARA THERAPEUTICS INC (CDTX) currently has 38 employees.


What are the support and resistance levels for CIDARA THERAPEUTICS INC (CDTX) stock?

CIDARA THERAPEUTICS INC (CDTX) has a support level at 61.78. Check the full technical report for a detailed analysis of CDTX support and resistance levels.


Is CIDARA THERAPEUTICS INC (CDTX) expected to grow?

The Revenue of CIDARA THERAPEUTICS INC (CDTX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the CDTX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CIDARA THERAPEUTICS INC (CDTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CIDARA THERAPEUTICS INC (CDTX) stock pay dividends?

CDTX does not pay a dividend.


When does CIDARA THERAPEUTICS INC (CDTX) report earnings?

CIDARA THERAPEUTICS INC (CDTX) will report earnings on 2025-08-11.


What is the Price/Earnings (PE) ratio of CIDARA THERAPEUTICS INC (CDTX)?

CIDARA THERAPEUTICS INC (CDTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-10.87).


What is the Short Interest ratio of CIDARA THERAPEUTICS INC (CDTX) stock?

The outstanding short interest for CIDARA THERAPEUTICS INC (CDTX) is 11.36% of its float. Check the ownership tab for more information on the CDTX short interest.


CDTX Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to CDTX. When comparing the yearly performance of all stocks, CDTX is one of the better performing stocks in the market, outperforming 99.35% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CDTX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CDTX. CDTX has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CDTX Financial Highlights

Over the last trailing twelve months CDTX reported a non-GAAP Earnings per Share(EPS) of -10.87. The EPS decreased by -41.54% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -95.44%
ROE -129.15%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%27.19%
Sales Q2Q%-100%
EPS 1Y (TTM)-41.54%
Revenue 1Y (TTM)-99.35%

CDTX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to CDTX. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of 29.41% and a revenue growth -100% for CDTX


Ownership
Inst Owners86.21%
Ins Owners1.55%
Short Float %11.36%
Short Ratio2.78
Analysts
Analysts84.62
Price Target60.35 (-4.68%)
EPS Next Y29.41%
Revenue Next Year-100%